Key result
Sodium-glucose cotransporter-2 inhibitor use was associated with significantly greater left ventricular global longitudinal strain at 6 months compared to standard treatment (18.41% vs 16.90%, p < 0.001).
Why the study?
The study aimed to elucidate the impact of SGLT2i on left ventricular systolic function using global longitudinal strain in type 2 diabetes mellitus patients and evaluate its protective effect according to disease duration.
Does sodium-glucose cotransporter-2 inhibitor improve left ventricular global longitudinal strain in patients with type 2 diabetes mellitus without cardiovascular complications?
Observational (n=256)
Single-blind
No
Does sodium-glucose cotransporter-2 inhibitor improve left ventricular global longitudinal strain in patients with type 2 diabetes mellitus without cardiovascular complications?
Absolute Event Rate: 18.41% vs 16.9%
p-value: p=<0.001
SGLT2 inhibitors significantly improve left ventricular global longitudinal strain in patients with type 2 diabetes mellitus without cardiovascular complications, particularly in early-stage disease.
SGLT2i may preserve GLS in uncomplicated T2DM; leaves open duration-dependent effects and practice change pending RCTs.
Our study aimed to elucidate the impact of sodium-glucose cotransporter-2 inhibitor on left ventricular systolic function using global longitudinal strain in type 2 diabetes mellitus patients and to assess its protective effect depending on disease duration. Type 2 diabetes mellitus patients treated at our institute were included. According to whether sodium-glucose cotransporter-2 inhibitor was used in drug treatment, the patients were divided into SGLT2i group and control group, and propensity score matching was performed. For subgroup analysis, patients were further classified based on disease duration (1-5 years, 5-10 years, and 10-20 years). A total of 256 patients with type 2 diabetes mellitus were enrolled. Significantly better global longitudinal strain results were observed at the 6-month follow-up in the SGLT2i group than those of the control group and its baseline (p < 0.001). A significantly lower proportion of subclinical cardiac dysfunction was observed in the SGLT2i group (p < 0.001). Significantly greater global longitudinal strains were observed in the SGLT2i subgroups compared with control subgroups (p all < 0.05). Furthermore, sodium-glucose cotransporter-2 inhibitor use and epicardial adipose tissue thickness change were independently associated with global longitudinal strain change according to multivariate analysis. Sodium-glucose cotransporter-2 inhibitor significantly improved left ventricular function in type 2 diabetes mellitus patients without cardiovascular complications, regardless of disease duration, with more prominent outcomes observed in patients with early-stage disease.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) conducted an observational in Type 2 diabetes mellitus without cardiovascular diseases (n=256). Sodium-glucose cotransporter-2 inhibitor vs. Standard treatment without SGLT2 inhibitors was evaluated on Global longitudinal strain at 6 months (p=<0.001). Sodium-glucose cotransporter-2 inhibitor use was associated with significantly greater left ventricular global longitudinal strain at 6 months compared to standard treatment (18.41% vs 16.90%, p < 0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: